Trial Profile
A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2022
Price :
$35
*
At a glance
- Drugs PF-06804103 (Primary) ; Letrozole; Palbociclib
- Indications Breast cancer; Gastric cancer; HER2 negative breast cancer; HER2 positive breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 23 Sep 2021 Status changed from recruiting to completed.
- 17 Aug 2021 Planned End Date changed from 31 Aug 2021 to 26 Aug 2021.
- 17 Aug 2021 Planned primary completion date changed from 31 Aug 2021 to 26 Aug 2021.